Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M

Gossamer Bio, Inc.

2025-Q1 EPS reported -$0.16 revenue$9,889,000

Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.
Baseline characteristics align with target: mean 6MWD 376 m, 74% Functional Class III, NT-proBNP 986 ng/L.
Phase 3 SERANATA study in PH-ILD to begin site activations in Q4 2025 with ~480 patients.
Cash $257.9M expected to fund operations into H1 2027; Q1 net loss $36.6M ($0.16/share).
Revenue from Chiesi collaboration $9.9M ($6.6M cost reimbursement); R&D expenses $38.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.